My Portfolio

BioMarin Pharmaceutical Inc BMRN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 4:00 PM EDT

54.66UNCH (UNCH)

Volume

417,562

54.66

+1.34 (+2.51%)

Volume

1,849,750

52 week range

49.26 - 66.28

Open53.32
Day High55.00
Day Low53.01
Prev Close53.32
52 Week High66.28
52 Week High Date02/24/26
52 Week Low49.26
52 Week Low Date05/18/26

Latest On BioMarin Pharmaceutical Inc

Morgan Stanley says these stocks could outperform if they initiate a dividendMay 29, 2026CNBC.com
Rare disease families find roadmap to drug development at bootcampsMay 7, 2026CNBC.com
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trialApril 27, 2026CNBC.com
How CNBC Cures is bringing rare disease stories to a national audienceMarch 20, 2026CNBC.com
FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington'sMarch 5, 2026CNBC.com
FDA watchers warn of agency in 'chaos' and risk to America's healthMarch 3, 2026CNBC.com
Tuesday’s stock stories: What’s likely to move the market in the next sessionJuly 7, 2025CNBC.com
6 stocks to buy for the second half, according to Wall Street analystsJune 22, 2025CNBC.com
Lightning Round: I don't want to buy enterprise software right now, says Jim CramerJune 11, 2025CNBC.com
Cramer's Lightning Round: Union Pacific is a buyJune 11, 2025CNBC.com

Key Stats

Market Cap10.565B
Shares Out193.28M
10 Day Average Volume2.87M
Dividend-
Dividend Yield-
Beta0.24

Latest On BioMarin Pharmaceutical Inc

Morgan Stanley says these stocks could outperform if they initiate a dividendMay 29, 2026CNBC.com
Rare disease families find roadmap to drug development at bootcampsMay 7, 2026CNBC.com
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trialApril 27, 2026CNBC.com
How CNBC Cures is bringing rare disease stories to a national audienceMarch 20, 2026CNBC.com
FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington'sMarch 5, 2026CNBC.com
FDA watchers warn of agency in 'chaos' and risk to America's healthMarch 3, 2026CNBC.com
Tuesday’s stock stories: What’s likely to move the market in the next sessionJuly 7, 2025CNBC.com
6 stocks to buy for the second half, according to Wall Street analystsJune 22, 2025CNBC.com
Lightning Round: I don't want to buy enterprise software right now, says Jim CramerJune 11, 2025CNBC.com
Cramer's Lightning Round: Union Pacific is a buyJune 11, 2025CNBC.com

KEY STATS

Open53.32
Day High55.00
Day Low53.01
Prev Close53.32
52 Week High66.28
52 Week High Date02/24/26
52 Week Low49.26
52 Week Low Date05/18/26
Market Cap10.565B
Shares Out193.28M
10 Day Average Volume2.87M
Dividend-
Dividend Yield-
Beta0.24

RATIOS/PROFITABILITY

EPS (TTM)1.37
P/E (TTM)39.88
Fwd P/E (NTM)11.81
EBITDA (TTM)851.377M
ROE (TTM)4.48%
Revenue (TTM)3.242B
Gross Margin (TTM)80.21%
Net Margin (TTM)8.29%
Debt To Equity (MRQ)23.02%

EVENTS

Earnings Date08/03/2026(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Content From Our Affiliates

BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim15 Hours AgoTipRanks
3 Best Stocks to Buy This Week, According to Analysts – May 25-May 29May 25, 2026TipRanks
BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel NicolausMay 24, 2026TipRanks
Wall Street Analysts Are Bullish on Top Healthcare PicksMay 23, 2026TipRanks
BioMarin price target lowered to $111 from $116 at CanaccordMay 22, 2026TipRanks

Profile

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan...

Richard Meier

Non-Executive Independent Chairman of the Board

Ian Clark

Independent Chairman of the Board

Alexander Hardy

President, Chief Executive Officer, Director

Brian Mueller CPA

Chief Financial Officer, Executive Vice President

Rashmi Ramchandani

Chief Accounting Officer, Vice President

Cristin Hubbard

Executive Vice President, Chief Commercial Officer

Address

770 Lindaro Street

San Rafael, CA

94901

United States

https://www.biomarin.com/